Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

Oric Pharmaceuticals reported that its drug enozertinib showed an 88% response rate in a study for EGFR lung cancer. The company plans to start a Phase 3 trial in 2027 and estimates a $2.5B U.S. market opportunity. Oric also continues studying enozertinib for other cancer types.

Original reporting
Published Oct 23, 2026, 5:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 5:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study — source image
Decision brief

The 30-second read

$ORICBullishMed
01

Why it matters

The 88% response rate is a strong signal for potential accelerated approval, likely prompting short‑term buying interest.

02

Market read

Positive early‑stage data may drive ORIC stock higher and influence peer biotech valuations.

03

What to watch

Regulatory timeline and competition from other EGFR inhibitors could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Oric Pharmaceuticals (NASDAQ:ORIC) is a clinical‑stage biotech focusing on resistance mechanisms in cancer. The company announced Phase 1b results for its oral EGFR inhibitor enozertinib.

Company-level read

Ticker impact

$ORICBullishHigh confidence
Context

Oric Pharmaceuticals reported an 88% response rate for enozertinib in its Phase 1b EGFR lung‑cancer study.

Expected impact

likely upside as investors price in potential accelerated approval path

Evidence & confidence

Phase 1b response rate is unusually high; market typically rewards biotech firms with strong early data.

Market effects

Boosts sentiment for EGFR‑targeted oncology assets and may lift peer biotech valuations.

U.S. biotech sector could see modest gains.

Limited to biotech investors; no broad market effect.

Counterpoint

Data are early‑stage; efficacy may not translate to Phase 3, so price could be overstated.

Key entities

  • Oric Pharmaceuticals

    Clinical‑stage biotech developing enozertinib for atypical EGFR NSCLC.

  • Jacob Chacko

    CEO of Oric, quoted on the data.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo